Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Vistagen Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -2474.5%. For fiscal 2026 it was -5491.3%, against -10579.8% the year before. The highest annual figure on record is -457.9% in fiscal 2011.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -5491.3% | +5088.5 |
| FY2025 | Mar 31, 2025 | -10579.8% | −7820.2 |
| FY2024 | Mar 31, 2024 | -2759.6% | +1547.2 |
| FY2022 | Mar 31, 2022 | -4306.8% | −2660.7 |
| FY2021 | Mar 31, 2021 | -1646.1% | −825.7 |
| FY2017 | Mar 31, 2017 | -820.4% | +5610.0 |
| FY2013 | Mar 31, 2013 | -6430.5% | −5520.8 |
| FY2012 | Mar 31, 2012 | -909.7% | −451.8 |
| FY2011 | Mar 31, 2011 | -457.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -7782.6% | −256.6 |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -882.8% | +5303.7 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -3499.8% | +2521.2 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -6237.3% | +845.2 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -7526.0% | +5251.4 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -6186.5% | −1353.5 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -6020.9% | −4475.9 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -7082.5% | −4712.7 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -12777.4% | −8877.4 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -4833.0% | +2114.2 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -1545.0% | +3877.9 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -2369.8% | +4007.6 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -3900.0% | +38889.7 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -6947.2% | −4004.7 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -5422.9% | −1848.9 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -6377.4% | −4189.5 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -42789.7% | −41384.5 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -2942.5% | −1252.8 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -3574.0% | −2586.7 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -2187.9% | −1976.8 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -1405.2% | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -1689.6% | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -987.4% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -211.0% | – |
See a number that looks wrong?